barda funding for rival antiviral, page-7

Cgt

BARDA and other authorities are keen enough (I'm sure) to have multiple irons in the fire - these other grants mentioned today are peanuts, but still helpful enough to allow those companies to continue to progress their drugs.

According to PC, Biota has not progressed Flunet because it "overlaps" LANI. Flunet is, however, next gen beyond LANI (certainly in potency), however, we saw what foresight Biota had in terms of life beyond Relenza - result => Relenza patent expiry window and black hole before LANI comes on board ROW...

...foresight is not a strong point of PC's, then again, I'm not sure what is...